|Bid||83.08 x 1100|
|Ask||83.11 x 800|
|Day's Range||82.50 - 85.33|
|52 Week Range||29.68 - 99.00|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.67|
Joining me today are Glaukos President and CEO, Tom Burns; CFO, Joe Gilliam; and COO, Chris Calcaterra. To ensure ample time and opportunity to address everyone's questions, we request that you limit yourself to one question and one follow-up.
Glaukos (GKOS) delivered earnings and revenue surprises of 30.00% and 4.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: